Abstract
The objective of this study was to develop a physiologically based pharmacokinetic (PBPK) model for sinogliatin (HMS-5552, dorzagliatin) by integrating allometric scaling (AS), in vitro to in vivo exploration (IVIVE), and steady-state concentration–mean residence time (Css-MRT) methods and to provide mechanistic insight into its pharmacokinetic properties in humans.
Funding Information
  • National Natural Science Foundation of China (81403013, 81403015)
  • "13th Five-Year" National Major New Drug Projects (2017ZX09101001-002-001, 2017ZX09304031-001)

This publication has 32 references indexed in Scilit: